Cystatin C vs creatinine eGFR in advanced CKD: an analysis of the STOP-ACEi trial
Our results are consistent with the primary study's analysis and sensitivity analyses support these findings and provide additional insights. Our findings demonstrate the similarity of creatinine and cystatin eGFR results and therefore support the use of cystatin C as an alternative marker of eGFR in advanced CKD, particularly in those in whom creatinine is likely to be less accurate.
Authors
- Samir Mehta (ORCID: https://orcid.org/0000-0001-7096-513X)
- Robert Desborough (ORCID: https://orcid.org/0009-0004-8964-9144)
- Sebastian Spencer (ORCID: https://orcid.org/0000-0001-8569-773X)
- Sunil Bhandari (ORCID: https://orcid.org/0000-0002-0996-9622)
- Natalie Ives (ORCID: https://orcid.org/0000-0002-1664-7541)
Institutions
- University of Hull (GB)
- University Teaching Hospital (ZM)
- Cancer Research UK Clinical Trials Unit (GB)
- Hull York Medical School (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1093/ckj/sfae268
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00